Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy
Authors' conclusion
Triple regression occurred in one-third of patients with acute myocardial infarction who were receiving high-intensity lipid-lowering therapy and was associated with alirocumab treatment, higher baseline lipid content, and reduced cardiovascular events.
Study context
- Population
- Patients with acute MI receiving high-intensity lipid-lowering therapy
- Comparison
- Triple regression vs no triple regression; alirocumab vs placebo
- Primary endpoint
- Triple regression (reduction in percentage atheroma volume and maximum lipid core burden index within 4 mm, increase in minimal fibrous cap thickness)
Methodological detailsserial intravascular imaging (IVUS, NIRS, OCT)
- Serial intravascular imaging (IVUS, NIRS, OCT)
Primary result
As reported in the abstract
Triple regression
P = 0.002
- Overall triple regression
- 84 patients (31.7%)
Further findings
| Outcome | Between-group difference (mg/dL) (95% CI) | P value | |
|---|---|---|---|
| On-treatment LDL-C, triple regressionvs none | −27.1 (−37.7 to −16.6) | P < 0.001 | |
| −40−20020Difference, mg/dL (linear scale) |
Composite of death, MI and ischemia-driven revascularization · 1 year
P = 0.04
Independent predictors of triple regression
- Alirocumab treatment: OR 2.83 (95% CI 1.57-5.16)
- P = 0.001
- Higher baseline maximum lipid core burden index within 4 mm: OR 1.03 (95% CI 1.01-1.06)
- P = 0.013
Original publication
Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy. J Am Coll Cardiol. Published 26 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →